CB1 cannabinoid receptors mediate anxiolytic effects: Convergent genetic and pharmacological evidence with CB1-specific agents

Behavioural Pharmacology

Volumn 15, Issue 4, 2004, Pages 299-304

  Haller, J ^a   Varga, B ^a   Ledent, C ^b   Freund, T F ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

212 2; AM 251; Anxiety; Behaviour; Cannabinoid; CB1 KO; Mouse; Plus maze; WIN 55

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; RIMONABANT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; BEHAVIOR GENETICS; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG MIXTURE; KNOCKOUT MOUSE; LOCOMOTION; MALE; MAZE TEST; MOUSE; NONHUMAN; STRAIN DIFFERENCE; TRANQUILIZING ACTIVITY; WILD TYPE;

EID: 4043145966     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fbp.0000135704.56422.40     Document Type: Article

References (48)

1. Akinshola BE, Chakrabarti A, Onaivi ES (1999). In-vitro and in-vivo action of cannabinoids. Neurochem Res 24:1233-1240.
2. Baker D, Pryce G, Giovannoni G, Thompson AJ (2003). The therapeutic potential of cannabis. Lancet Neurol 2:291-298.
3. Bloom FE, Morales M (1998). The central 5-HT3 receptor in CNS disorders. Neurochem Res 23:653-659.
4. Breivogel CS, Griffin G, Di Marzo V, Martin BR (2001). Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60:155-163.
5. Capanna E, Corti M, Mainardi D, Parmigiani S, Brain PF (1984). Karyotype and intermale aggression in wild house mice: ecology and speciation. Behav Genet 14:195-208.
6. 3 receptors. Pharmacol Ther 47:181-202.
7. Costall B, Domeney AM, Hughes J, Kelly ME, Naylor RJ, Woodruff GN (1991). Anxiolytic effects of CCK-B antagonists. Neuropeptides 19 (suppl):65-73.
8. Crawley JN, Corwin RL, Robinson JK, Felder CC, Devane WA, Axelrod J (1993). Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol Biochem Behav 46:967-972.
9. Cryan JF, Gasparini F, van Heeke G, Markou A (2003). Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion. Drug Discov Today 8:1025-1034.
10. Di Marzo V, Breivogel CS, Tao Q, Bridgen DT, Razdan RK, Zimmer AM, et al. (2000). Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem 75:2434-2444.
11. Drysdale AJ, Platt B (2003). Cannabinoids: mechanisms and therapeutic applications in the CNS. Curr Med Chem 10:2719-2732.
12. Ferrari PF, Palanza P, Parmigiani S, Rodgers RJ (1998). Interindividual variability in Swiss male mice: relationship between social factors, aggression, and anxiety. Physiol Behav 63:821-827.
13. File SE, Kenny PJ, Cheeta S (2000). The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety. Pharmacol Biochem Behav 66:65-72.
14. Fink H, Rex A, Voits M, Voigt JP (1998). Major biological actions of CCK - a critical evaluation of research findings. Exp Brain Res 123:77-83.
15. Freund TF (2003). Interneuron diversity series: rhythm and mood in perisomatic inhibition. Trends Neurosci 26:489-495.
16. Gaetani S, Cuomo V, Piomelli D (2003). Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends Mol Med 9:474-478.
17. Goya P, Jagerovic N, Hernandez-Folgado L, Martin MI (2003). Cannabinoids and neuropathic pain. Mini Rev Med Chem 3:765-772.
18. Hájos N, Freund TF (2002). Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology 43:503-510.
19. Hájos N, Ledent C, Freund TF (2001). Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106:1-4.
20. Haller J, Bakos N, Szirmay M, Ledent C, Freund TF (2002). The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 16:1395-1398.
21. Harrold JA, Williams G (2003). The cannabinoid system: a role in both the homeostatic and hedonic control of eating? Br J Nutr 90:729-734.
22. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. (1990). Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932-1936.
23. Hilakivi LA, Ota M, Lister RG (1989). Effect of isolation on brain monoamines and the behaviour of mice in tests of exploration, locomotion, anxiety and behavioural 'despair'. Pharmacol Biochem Behav 33:371-374.
24. Hogg S (1996). A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol Biochem Behav 45:21-30.
25. Jarai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, et al. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 96:14136-14141.
26. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nature Med 9:76-81.
27. Katona I, Sperlagh B, Sík A, Kafalví A, Vizí ES, Mackie K, et al. (1999). Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19:4544-4558.
28. Katona I, Rancz EA, Acsady L, Ledent C, Mackie K, Hajos N, et al. (2001). Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci 21:9506-9518.
29. 3H]glutamate from rodent hippocampal synaptosomes via a novel CB1 receptor-independent action. Eur J Neurosci 18:1973-1978.
30. Lastres-Becker I, De Miguel R, Fernandez-Ruiz JJ (2003). The endocannabinoid system and Huntington's disease. Curr Drug Target CNS Neurol Disord 2:335-347.
31. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, et al. (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401-404.
32. Low K, Crestani F, Keist R, Benke D, Brunig I, Benson JA, et al. (2000). Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290:131-134.
33. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2002). Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 159:379-387.
34. Mauler F, Horvath E, De Vry J, Jager R, Schwarz T, Sandmann S, et al. (2003). BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury. CNS Drug Rev 9:343-358.
35. Millan MJ (2003). The neurobiology and control of anxious states. Prog Neurobiol 70:83-244.
36. Morales M, Bloom FE (1997). The 5-HT3 receptor is present in different subpopulations of GABAergic neurons in the rat telencephalon. J Neurosci 17:3157-3167.
37. Navarro M, Hernandez E, Munoz RM, del Arco I, Villanua MA, Carrera MR, et al. (1997). Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 8:491-496.
38. Nunes-de-Souza RL, Canto-de-Souza A, Rodgers RJ (2002). Effects of intrhippocampal infusion of WAY-100635 on plus-maze behaviour in mice. Influence of site of injection and prior test experience. Brain Res 927:87-96.
39. Nyiri G, Freund TF, Somogyi P (2001). Input-dependent synaptic targeting of alpha(2)-subunit-containing GABA(A) receptors in synapses of hippocampal pyramidal cells of the rat. Eur J Neurosci 13:428-442.
40. Onaivi ES, Chakrabarti A, Gwebu ET, Chaudhuri G (1995). Neurobehavioural effects of delta 9-THC and cannabinoid (CB1) receptor gene expression in mice. Behav Brain Res 72:115-125.
41. Papp EC, Hájos N, Acsady L, Freund TF (1999). Medial septal and median raphe innervation of vasoactive intestinal polypeptide-containing interneurons in the hippocampus. Neuroscience 90:369-382.
42. Pistis M, Perra S, Pillolla G, Melis M, Gessa GL, Muntoni AL (2004). Cannabinoids modulate neuronal firing in the rat basolateral amygdala: evidence for CB1- and non-CB1-mediated actions. Neuropharmacology 46:115-125.
43. A responses in hippocampal pyramidal cells. J Neurosci 12:4122-4132.
44. Poshivalov VP (1980). The integrity of the social hierarchy in mice following administration of psychotropic drugs. Br J Pharmacol 70:367-373.
45. Rodgers RJ, Cole JC (1993). Influence of social isolation, gender, strain, and prior novelty on plus-maze behaviour in mice. Physiol Behav 54:729-736.
46. Scatton B, Sanger DJ (2000). Pharmacological and molecular targets in the search for novel antipsychotics. Behav Pharmacol 11:243-256.
47. Wilson RI, Nicoll RA (2001). Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410:588-592.
48. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner T (1999). Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96:5780-5785.